Hyloris Pharmaceuticals SA engages in the provision of development and reformulating of pharmaceutical products. It offers commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a novel, dual modeof-action non-opioid analgesic for the treatment of post-operative pain. The company was founded by Stijn van Rompay and Thomas Jacobsen in 2012 and is headquartered in Liege, Belgium.